GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate

Rheumatology (United Kingdom)

Volumn 52, Issue 10, 2013, Pages 1890-1897

  Castrejón, Isabel ^a   Pincus, Theodore ^a   Soubrier, Martin ^b   Lin, Yih Chang ^c   Rat, Anne Christine ^d   Combe, Bernard ^e   Dougados, Maxime ^f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SERVICE DE RHUMATOLOGIE   (France)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITÉ DE LORRAINE   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f Institut Cochin   (France)

Author keywords

Assessment; Patient questionnaires; Patient reported outcomes; Rheumatoid arthritis; Treat to target

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; GLUCOCORTICOID; METHOTREXATE; PREDNISOLONE;

ADULT; ARTICLE; BONE EROSION; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERMETHOD COMPARISON; JOINT CAVITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MODIFIED SHARP VAN DER HEIJDE SCORE; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL SYSTEM PARAMETERS; OUTCOME ASSESSMENT; PAIN; PATIENT ASSESSMENT; PATIENT CARE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SCORING SYSTEM; TENDER JOINT COUNT; VISUAL ANALOG SCALE;

EID: 84887383393     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket230     Document Type: Article

References (23)

1. Pincus T, Yazici Y, Sokka T. Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Rheum Dis Clin North Am 2009;35:687-97.
2. Felson DT. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. J Rheumatol 1993;20:531-4.
3. Prevoo MLL, Van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
4. Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009;35:731-4.
5. Aletaha D, Nell VPK, Stamm T et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
6. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100-8.
7. Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009;68:972-5.
8. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2.
9. Pincus T, Strand V, Koch G et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003;48:625-30.
10. Pincus T, Chung C, Segurado OG et al. An index of patient self-reported outcomes (PRO Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006;33:2146-52.
11. Pincus T, Bergman MJ, Yazici Y et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology 2008;47:345-9.
12. Pincus T, Furer V, Keystone E et al. RAPID3 (routine assessment of patient index data) severity categories and response criteria: similar results to DAS28 and CDAI in the RAPID1 (rheumatoid arthritis prevention of structural damage) clinical trial of certolizumab pegol (CZP). Arthritis Care Res 2011;63:1142-9.
13. Pincus T, Swearingen CJ, Bergman MJ et al. RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res 2010;62:181-9.
14. Schipper LG, van Hulst LT, Grol R et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology 2010;49:2154-64.
15. Soubrier M, Lukas C, Sibilia J et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011;70:611-5.
16. Combe B, Benessiano J, Berenbaum F et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
17. Tugwell P, Wells G, Strand V et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000;43:506-14.
18. Wells G, Li T, Maxwell L et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008;67:260-5.
19. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
21. Pincus T, Swearingen CJ, Bergman M et al. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to DAS and CDAI categories. J Rheumatol 2008;35:2136-47.
22. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
23. Pincus T, Yazici Y, Bergman MJ. Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical history. Rheum Dis Clin North Am 2009;35:735-43.